Literature DB >> 16985624

Quality of life and sexual function in patients with benign prostatic hyperplasia.

Reginald C Bruskewitz.   

Abstract

Incidence of benign prostatic hyperplasia (BPH), one of the most common conditions affecting adult men, increases dramatically after the age of 50. The various symptoms of BPH, which include lower urinary tract symptoms (LUTS), can adversely affect quality of life (QOL). Many men with BPH and LUTS wait until symptoms become significantly bothersome before seeking medical attention. Evaluating the exact severity and significance of symptoms has been difficult with previous methodology. Over the last decade, assessment tools have become available to quantify the symptoms of BPH and LUTS. This article addresses the impact of BPH, its management, and the overall effects it has on QOL.

Entities:  

Year:  2003        PMID: 16985624      PMCID: PMC1473005     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  52 in total

Review 1.  Phytotherapy in the treatment of benign prostatic hyperplasia: an update.

Authors:  F C Lowe; E Fagelman
Journal:  Urology       Date:  1999-04       Impact factor: 2.649

Review 2.  Comprehensive patient evaluation for benign prostatic hyperplasia.

Authors:  J V Jepsen; R C Bruskewitz
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

3.  Pathophysiology of benign prostatic hyperplasia.

Authors:  F Algaba
Journal:  Eur Urol       Date:  1994       Impact factor: 20.096

4.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

5.  One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.

Authors:  B Lukacs; J C Grange; D Comet
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

6.  Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy.

Authors:  J Baniel; S Israilov; J Shmueli; E Segenreich; P M Livne
Journal:  Eur Urol       Date:  2000-07       Impact factor: 20.096

Review 7.  Sexual dysfunction in patients with benign prostatic hyperplasia.

Authors:  T M Downs; M P O'Leary
Journal:  Curr Opin Urol       Date:  1999-01       Impact factor: 2.309

8.  Sexual dysfunction in the United States: prevalence and predictors.

Authors:  E O Laumann; A Paik; R C Rosen
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

9.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

10.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.

Authors:  P Abrams; C C Schulman; S Vaage
Journal:  Br J Urol       Date:  1995-09
View more
  9 in total

1.  Prostatic Artery Embolization Allows to Maintain Full Sexual Activity in Patients Suffering from Bothersome Lower Urinary Tracts Symptoms related to Benign Prostatic Hyperplasia.

Authors:  Ludovica Marzano; Nicolas Thiounn; Helena Pereira; Olivier Pellerin; Charles Dariane; Costantino Del Giudice; Gregory Amouyal; Carol Dean; Marc Sapoval
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-03       Impact factor: 2.740

2.  Effect of tamsulosin on testis histopathology and serum hormones in adult rats: Experimental study.

Authors:  Yegane Kohestani; Bentolhoda Kohestani; Zahra Shirmohamadi; Masoumeh Faghani
Journal:  Int J Reprod Biomed       Date:  2020-07-22

3.  Quality of life in sexually active men with symptomatic benign prostatic hyperplasia : effects of treatment.

Authors:  Mel P Daly
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

4.  Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia.

Authors:  Negin Hadi; Alireza Aminsharifi; Ali Sadeghi; Ali Tourchi
Journal:  Qual Life Res       Date:  2012-09-05       Impact factor: 4.147

Review 5.  Drugs for benign prostatic hypertrophy.

Authors:  Manasi Jiwrajka; William Yaxley; Sachinka Ranasinghe; Marlon Perera; Matthew J Roberts; John Yaxley
Journal:  Aust Prescr       Date:  2018-10-01

6.  Changes in Erectile Function after Photoselective Vaporization of the Prostate with a 120-W GreenLight High-Performance System Laser: 2-Year Follow-Up.

Authors:  Juhyun Park; Sung Yong Cho; Min Chul Cho; Hyeon Jeong; Hwancheol Son
Journal:  World J Mens Health       Date:  2017-11-16       Impact factor: 5.400

7.  Ex vivo study of Ho:YAG and thulium fiber lasers for soft tissue surgery: which laser for which case?

Authors:  Mark Taratkin; Anastasia Kovalenko; Ekaterina Laukhtina; Nina Paramonova; Leonid Spivak; Luca Johann Wachtendorf; Semil Eminovic; Andrew Sheya Afyouni; Zhamshid Okhunov; Marina Karagezyan; Vasily Mikhailov; Yuriy Strakhov; Thomas Rw Herrmann; Dmitry Enikeev
Journal:  Lasers Med Sci       Date:  2020-11-11       Impact factor: 3.161

8.  Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial.

Authors:  Yang Wang; Baoyan Liu; Jinna Yu; Jiani Wu; Jing Wang; Zhishun Liu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

9.  Implementation of a nurse-led lower urinary tract symptoms (LUTS) clinic reduces general urology clinic workload in a Model 4 Hospital: a pilot study in Tallaght University Hospital.

Authors:  Kevin G Keane; Mohammud Shakeel Inder; Caroline McIntyre; Shawgi Omer; Elizabeth McEvoy; Lisa G Smyth; Rowan G Casey; Arun Z Thomas; Rustom P Manecksha; Robert J Flynn
Journal:  Ir J Med Sci       Date:  2020-11-14       Impact factor: 2.089

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.